Fmr Llc - Jun 21, 2021 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Other*
Signature
Kevin M. Meagher, Duly authorized under Powers of Attorney, by and on behalf of FMR LLC and its direct and indirect subsidiaries, and Abigail P. Johnson
Stock symbol
VERV
Transactions as of
Jun 21, 2021
Transactions value $
$0
Form type
4
Date filed
6/23/2021, 11:36 AM
Previous filing
Jun 16, 2021
Next filing
Jul 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Conversion of derivative security +134K 134K Jun 21, 2021 F-Prime Capital Partners Healthcare Fund V LP F1
transaction VERV Common Stock Conversion of derivative security +903K +672.32% 1.04M Jun 21, 2021 F-Prime Capital Partners Healthcare Fund V LP F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Series A-2 Preferred Stock Conversion of derivative security -1.24M -100% 0 Jun 21, 2021 Common Stock 134K F-Prime Capital Partners Healthcare Fund V LP F1
transaction VERV Series A Preferred Stock Conversion of derivative security -8.36M -100% 0 Jun 21, 2021 Common Stock 903K F-Prime Capital Partners Healthcare Fund V LP F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Fmr Llc is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 On June 21, 2021 , in connection with the completion of the issuer's initial public offering, each 9.2595 shares of Series A and A-2 Preferred Stock converted into 1 share of Common Stock.

Remarks:

Remark 1: Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein. Remark 3: The general partner of F-Prime Capital Partners Healthcare Fund V LP is F-Prime Capital Partners Healthcare Advisors Fund V LP (FPCPHA). FPCPHA is solely managed by Impresa Management LLC, the managing member of its general partner and its investment manager. Impresa Management LLC is owned, directly or indirectly, by various shareholders and employees of FMR LLC, including certain members of the Johnson family.